Novavax (NVAX) versus DBV TECHNOLOGIE/S (DBVT) Financial Contrast

Novavax (NASDAQ:NVAX) and DBV TECHNOLOGIE/S (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares Novavax and DBV TECHNOLOGIE/S’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $31.18 million 24.68 -$183.76 million ($0.63) -3.19
DBV TECHNOLOGIE/S $13.45 million 61.62 -$166.93 million ($3.37) -4.31

DBV TECHNOLOGIE/S has lower revenue, but higher earnings than Novavax. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Novavax has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, DBV TECHNOLOGIE/S has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Insider & Institutional Ownership

40.9% of Novavax shares are owned by institutional investors. Comparatively, 45.4% of DBV TECHNOLOGIE/S shares are owned by institutional investors. 3.4% of Novavax shares are owned by insiders. Comparatively, 15.3% of DBV TECHNOLOGIE/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Novavax and DBV TECHNOLOGIE/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novavax -482.87% N/A -66.83%

Analyst Recommendations

This is a summary of current recommendations and price targets for Novavax and DBV TECHNOLOGIE/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax 0 2 6 0 2.75
DBV TECHNOLOGIE/S 0 1 5 0 2.83

Novavax currently has a consensus price target of $3.60, indicating a potential upside of 78.98%. DBV TECHNOLOGIE/S has a consensus price target of $36.40, indicating a potential upside of 150.52%. Given DBV TECHNOLOGIE/S’s stronger consensus rating and higher possible upside, analysts clearly believe DBV TECHNOLOGIE/S is more favorable than Novavax.


DBV TECHNOLOGIE/S beats Novavax on 8 of the 13 factors compared between the two stocks.

About Novavax

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with's FREE daily email newsletter.

Leave a Reply